ReviewFrontiers in pharmacology2022
Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- Self-assembled perylene diimide/CuO p-n heterojunction-enhanced photoelectrochemical platform for sensitive dopamine detection.Mikrochimica acta · 2026Article
- Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026Review
- Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.Clinical pharmacology and therapeutics · 2026Review
- Emerging Molecular Targets and Recent Advancements for the Management of Depression.Molecular neurobiology · 2026Review
- An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression.Translational psychiatry · 2026Article
- The WAG/Rij Rat Model of Depression Comorbid with Absence Epilepsy: Sex Differences and Neurochemical Mechanisms.International journal of molecular sciences · 2026Article
- The Genetic Mosaic of Depression: Linking Polymorphisms to Neuroplasticity and Stress Regulation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modulatory effects ofNutrition research and practice · 2026Article
- Modulating depression through the gut-brain axis: the role of gut microbiota in therapeutic interventions.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Proline Homologation in Melanostatin Neuropeptide: Discovery of Potent Modulators of the Dopamine DACS medicinal chemistry letters · 2025Article
- Mechanistic intersections between migraine and major depressive disorder.The journal of headache and pain · 2025Review
- Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Neurotransmitter and metabolic effects of interferon-alpha in association with decreased striatal dopamine in a non-human primate model of cytokine-Induced depression.Brain, behavior, and immunity · 2025Article
- The central role of microglia in major depressive disorder and its potential as a therapeutic target.Frontiers in behavioral neuroscience · 2025Review
- The Potential Role of Dopamine Pathways in the Pathophysiology of Depression: Current Advances and Future Aspects.CNS & neurological disorders drug targets · 2025Review
- Exploring Genetic and Receptor-Based Dopaminergic Strategies for Antidepressant Drug Development.Current gene therapy · 2025Review
- Integrating Molecular Biology and Network Pharmacology to Analyze the Antidepressant Mechanism of Glycyrrhizaglabra.Combinatorial chemistry & high throughput screening · 2025Article
- Exploration of neural mechanisms underlying antidepressant-like property ofCurrent research in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson's disease, schizophrenia, some drug use addictions, as well as depression. Dopamine receptors are widely distributed in various regions of the brain, but their role and exact contribution to neuropsychiatric diseases has not yet been thoroughly studied. Based on the types of dopamine receptors and their distribution in different brain regions, this paper reviews the current research status of the molecular, cellular and circuit mechanisms of dopamine and its receptors involved in depression. Multiple lines of investigation of these mechanisms provide a new future direction for understanding the etiology and treatment of depression and potential new targets for antidepressant treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.